A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma
2010
Objectives: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Sorafenib is considered the standard of care for patients with advanced HCC. Methods:&
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
8
References
6
Citations
NaN
KQI